# Paul Baas

Source: https://onco.cc/people/paul-baas/  
OnCo record `paul-baas` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years.

## Summary

Paul Baas was principal investigator of CheckMate 743, which showed nivolumab plus ipilimumab improves overall survival over platinum-pemetrexed in unresectable malignant pleural mesothelioma, the first positive first-line trial since 2004 and the basis for immunotherapy's approval in the disease. He has led ESMO and IASLC mesothelioma guidelines and chaired the IASLC mesothelioma staging work.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: mesothelioma; immunotherapy
- Role: Thoracic Oncologist, Netherlands Cancer Institute; Professor, University of Amsterdam
- Specialisms: Mesothelioma; Thoracic oncology; Immunotherapy; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- trials: [CheckMate 743](https://onco.cc/trials/checkmate-743/)

---
JSON: https://onco.cc/api/v1/entities/paul-baas.json